2-[(6S,12R,15R,17E,20R,23S,26S,28R)-15-amino-23-(2-amino-2-oxoethyl)-20-carbamoyl-28-hydroxy-6-[(4-hydroxy-3-nitrophenyl)methyl]-2,5,8,11,14,22,25-heptaoxo-1,4,7,10,13,21,24-heptazabicyclo[24.3.0]nonacos-17-en-12-yl]acetic acid | 1195752-68-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-[(6S,12R,15R,17E,20R,23S,26S,28R)-15-amino-23-(2-amino-2-oxoethyl)-20-carbamoyl-28-hydroxy-6-[(4-hydroxy-3-nitrophenyl)methyl]-2,5,8,11,14,22,25-heptaoxo-1,4,7,10,13,21,24-heptazabicyclo[24.3.0]nonacos-17-en-12-yl]acetic acid
• CAS: 1195752-68-1
• 化学式: C₃₄H₄₅N₁₁O₁₅
• 分子量: 847.796
• InChiKey: FXHYTEUWLDPCQY-XYUJUEHESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -7.2
• 重原子数：
  60
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  431
• 氢给体数：
  12
• 氢受体数：
  16

反应信息

• 作为产物：
  描述：

  Fmoc-甘氨酸 、 Fmoc-N-三苯甲基-L-天冬酰胺 、 N-芴甲氧羰基-D-天冬氨酸-4-叔丁酯 、 Fmoc-D-烯丙基甘氨酸 、 Fmoc-4-叔丁氧基-L-脯氨酸 、 Fmoc-3-硝基-L-酪氨酸 在 1-羟基苯并三唑 、 N,N'-二异丙基碳二亚胺 、 哌啶 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 2-[(6S,12R,15R,17E,20R,23S,26S,28R)-15-amino-23-(2-amino-2-oxoethyl)-20-carbamoyl-28-hydroxy-6-[(4-hydroxy-3-nitrophenyl)methyl]-2,5,8,11,14,22,25-heptaoxo-1,4,7,10,13,21,24-heptazabicyclo[24.3.0]nonacos-17-en-12-yl]acetic acid
  参考文献：
  名称：

  Structure −Activity Relationship Studies of Targeting Ligands against Breast Cancer Cells

  摘要：

  A series of LXY3 (1) analogues were designed and synthesized. Their binding affinity was demonstrated using MDA-MB-231 breast cancer cells adherence inhibition assay. Further structure-activity relationship was obtained. Analogue 29 was discovered to have 3.5-fold increase of the binding affinity. Fluorescent microscopy and in vivo and ex vivo imaging studies demonstrated that 29 is tin efficient in vivo targeting agent against alpha 3 integrin of MDA-MB-231 breast tumor xenograft implant.

  DOI：

  10.1021/jm9012032

文献信息

• Structure −Activity Relationship Studies of Targeting Ligands against Breast Cancer Cells
  作者：Nianhuan Yao、Wenwu Xiao、Leah Meza、Harry Tseng、Mathida Chuck、Kit S. Lam

  DOI：10.1021/jm9012032

  日期：2009.11.12

  A series of LXY3 (1) analogues were designed and synthesized. Their binding affinity was demonstrated using MDA-MB-231 breast cancer cells adherence inhibition assay. Further structure-activity relationship was obtained. Analogue 29 was discovered to have 3.5-fold increase of the binding affinity. Fluorescent microscopy and in vivo and ex vivo imaging studies demonstrated that 29 is tin efficient in vivo targeting agent against alpha 3 integrin of MDA-MB-231 breast tumor xenograft implant.